REMARKS

Amendments To The Claims

The claims have been amended in accord with the restriction requirement which is discussed below. Claim 1 was amended by replacing the phrase "the prodrugs thereof, and the pharmaceutically acceptable salts of said compounds or prodrugs" with the phrase "or a prodrug thereof, or a pharmaceutically acceptable salt of said compound or prodrug" and by addition of the phrase "each independently." Also, the definition of X and Y have been amended in claim 1 in order to change the punctuation within those variables, primarily by replacing semicolons with commas. Support for this amendment is in the specification as originally filed and in original claim 1.

Claims 2, 3 and 16 were amended by addition of the phrase "or a pharmaceutically acceptable salt thereof" to each of those claims. Support for these amendments is in the specification as originally filed.

Claim 2 was also amended by replacing "A" with "The" and by amending the definition of X and Y in order to change the punctuation within those variables, primarily by replacing semicolons with commas.

Claim 2 was also amended by replacing "A" with "The" and by amending the definition of X and Y in order to change the punctuation within those variables, primarily by replacing semicolons with commas.

Claim 6 was amended by replacing "disease," with "disease" and "carrier," with "carrier."

Claim 7 was amended by replacing "A" with "The", "reconstruction," with "reconstruction" and "bone fracture and/or defect" with "bone fracture, bone defect, bone fracture and bone defect."

Claim 8 was amended by replacing "A" with "The" and by addition of the phrase "bone defect or bone fracture and bone defect" and by deletion of the phrase "and/or defect." Support for this amendment is in the specification as originally filed, including original claim 8.

Claims 9-11, 15 and 19 were canceled without prejudice in accord with the restriction requirement.

Claim 12 was amended by addition of the phrase "a prodrug thereof, or a pharmaceutically acceptable salt of said" and by deletion of the pharmaceutical composition phrase.

Claim 13 was amended by replacing "A" with "The" and by replacing "said PDE 2 inhibitor" with "the compound of formula (I)."

Claims 14 and 20 were each amended by replacing the term "A" with "The."

Claim 16 was amended by replacing "A" with "The", by deletion of the definition of the variable X, and by amending the definition of the variable n and Y in order to change the punctuation within those variables, primarily by replacing semicolons with commas.

Claims 17 and 18 were amended by replacing "carrier," with "carrier."

New claim 21 was added. Support for this amendment is in the specification as originally filed, including original claim 4.

No new matter has been added by these amendments. Applicants reserve the right to file divisional or continuation applications, as appropriate, directed to the nonelected, canceled and deleted subject matter of this invention.

The Request for Disclosure of Prior Art

The Examiner has requested that Applicants disclose any prior art of which they are aware that discloses the compounds excluded by the proviso in claim 1, lines 5-6. Applicants respectfully submit that they are not aware of any prior art disclosure of the compounds excluded by the proviso in claim 1, lines 5-6.

The Restriction Requirement Under 35 U.S.C. § 121

Claims 1-20 are currently pending in this application. The Examiner has required restriction of the invention into one of three groups: Group I, claims 1-8, 12-14, 16-18 and 20, drawn to pyrido[2, 3-d]pyrimidine compounds, pharmaceutical compositions comprising them and pharmaceutical methods of using them; Group II, claims 9-11 and 19, drawn to pharmaceutical compositions comprising a PDE2 inhibitor and an EP2 selective receptor agonist and pharmaceutical methods of using them; and Group III, claim 15, drawn to a method of treating a bone fracture or bone defect or both with a PDE2 inhibitor.

Applicants hereby elect Group I.

Entry of the foregoing amendments to the claims is respectfully requested. An early and favorable response is respectfully solicited.

Respectfully submitted,

Date: 13 December 2007

/ John A. Wichtowski /
John A. Wichtowski
Attorney for Applicant(s)
Reg. No. 48,032

Pfizer Inc.
Patent Department
Eastern Point Road, MS 8260-1611
Groton, Connecticut 06340
(860) 715-6645